46 results on '"Falk, Daniel E."'
Search Results
2. Gabapentin Enacarbil Extended‐Release for Alcohol Use Disorder: A Randomized, Double‐Blind, Placebo‐Controlled, Multisite Trial Assessing Efficacy and Safety
3. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies
4. Posttreatment Low‐Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9‐Year Follow‐Up
5. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda
6. Advances in Pharmacotherapy Development: Human Clinical Studies
7. Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population
8. Five‐Year Healthcare Utilization and Costs Among Lower‐Risk Drinkers Following Alcohol Treatment
9. Posttreatment Low‐Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders
10. Posttreatment low-risk drinking as a predictor of future drinking and problem outcomes among individuals with alcohol use disorders.
11. Medication Development for Alcohol Use Disorder: A Focus on Clinical Studies
12. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda
13. Advances in Pharmacotherapy Development: Human Clinical Studies
14. Posttreatment Low‐Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders: A 9‐Year Follow‐Up
15. Differences Between Treatment‐Seeking and Nontreatment‐Seeking Alcohol‐Dependent Research Participants: An Exploratory Analysis
16. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels
17. Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis
18. Heterogeneity of Alcohol Use Disorder: Understanding Mechanisms to Advance Personalized Treatment
19. Methods to Analyze Treatment Effects in the Presence of Missing Data for a Continuous Heavy Drinking Outcome Measure When Participants Drop Out from Treatment in Alcohol Clinical Trials
20. Age of onset and temporal sequencing of lifetime DSM-IV alcohol use disorders relative to comorbid mood and anxiety disorders
21. An epidemiologic analysis of co-occurring alcohol and tobacco use and disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions
22. A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Varenicline Tartrate for Alcohol Dependence
23. A Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Levetiracetam Extended-Release in Very Heavy Drinking Alcohol-Dependent Patients
24. Medications development to treat alcohol dependence: a vision for the next decade
25. A Double-Blind, Placebo-Controlled Trial to Assess the Efficacy of Quetiapine Fumarate XR in Very Heavy-Drinking Alcohol-Dependent Patients
26. Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatment‐Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Varenicline
27. World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom
28. Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice
29. RACIAL/ETHNIC DIFFERENCES IN THE ASSOCIATION BETWEEN STRESSFUL LIFE EVENTS AND HAZARDOUS DRINKING: RESULTS FROM THE NESARC: 594
30. Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial
31. Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder
32. Five Priority Areas for Improving Medications Development for Alcohol Use Disorder and Promoting Their Routine Use in Clinical Practice.
33. Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article
34. Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the COMBINE Study
35. Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels
36. An exploratory evaluation of Take Control : A novel computer-delivered behavioral platform for placebo-controlled pharmacotherapy trials for alcohol use disorder
37. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
38. Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development
39. Potential Medications for the Treatment of Alcohol use Disorder: An Evaluation of Clinical Efficacy and Safety
40. Five-Year Healthcare Utilization and Costs Among Lower-Risk Drinkers Following Alcohol Treatment
41. Missing Data in Alcohol Clinical Trials with Binary Outcomes.
42. Posttreatment Low-Risk Drinking as a Predictor of Future Drinking and Problem Outcomes Among Individuals with Alcohol Use Disorders
43. A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence
44. Alcohol Consumption Among Breastfeeding Women
45. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.
46. The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and Goals for Assessing Important and Salient Issues for Medications Development in Alcohol Use Disorders.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.